Biogen (BIIB) PT Lowered to $400 After Speaking with Management, Jefferies Sees Street Consensus as Too High
Tweet Send to a Friend
Jefferies analyst Michael Yee lowered the price target on Biogen (NASDAQ: BIIB) to $400.00 (from $500.00) after speaking with management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
